Analysts Set bluebird bio, Inc. (NASDAQ:BLUE) Price Target at $4.63

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have received an average rating of “Hold” from the twelve brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $4.63.

A number of research firms have commented on BLUE. Barclays reduced their target price on bluebird bio from $8.00 to $4.00 and set an “overweight” rating on the stock in a report on Thursday, August 15th. Robert W. Baird reduced their price objective on bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a research note on Thursday, August 15th. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 target price on shares of bluebird bio in a research note on Thursday, August 15th. Cantor Fitzgerald reissued a “neutral” rating on shares of bluebird bio in a report on Monday, September 16th. Finally, JPMorgan Chase & Co. lowered shares of bluebird bio from an “overweight” rating to a “neutral” rating in a report on Thursday, August 15th.

bluebird bio Trading Down 5.1 %

NASDAQ BLUE opened at $0.46 on Tuesday. The company has a market capitalization of $50.73 million, a price-to-earnings ratio of -0.63 and a beta of 0.75. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.68 and a quick ratio of 0.57. bluebird bio has a 12 month low of $0.45 and a 12 month high of $5.53. The company’s fifty day moving average price is $0.53 and its two-hundred day moving average price is $0.83.

bluebird bio (NASDAQ:BLUE) last issued its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. The company had revenue of $18.57 million during the quarter. bluebird bio had a negative net margin of 567.29% and a negative return on equity of 207.25%. As a group, research analysts predict that bluebird bio will post -1.42 earnings per share for the current fiscal year.

Institutional Trading of bluebird bio

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in bluebird bio by 19.6% in the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock worth $13,438,000 after purchasing an additional 1,723,081 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of bluebird bio by 315.3% during the second quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock worth $1,223,000 after buying an additional 1,013,144 shares during the period. Bank of New York Mellon Corp boosted its position in shares of bluebird bio by 19.4% during the second quarter. Bank of New York Mellon Corp now owns 685,757 shares of the biotechnology company’s stock worth $675,000 after buying an additional 111,574 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in bluebird bio by 38.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company’s stock worth $416,000 after buying an additional 90,139 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in bluebird bio by 152.4% in the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 74,185 shares during the period. 87.43% of the stock is currently owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.